CCNG1 and neoplasm: Hypothesis: A brief administration of DeltaRex-G, a tumor targeted retroviral vector encoding a cytocidal mutated cyclin G1 gene, would inhibit only the dividing T cells thus reducing cytokine release by hyperactive CAR-T cells while retaining their antitumor efficacy.